- Home
- MDGL vs SRAD Comparison
MDGL vs SRAD Comparison
Compare MDGL & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | SRAD |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 3.8B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDGL | SRAD |
|---|---|---|
| Price | $536.34 | $12.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $674.45 | $24.31 |
| AVG Volume (30 Days) | 365.8K | ★ 2.8M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,133,000.00 | N/A |
| Revenue This Year | $58.39 | $24.03 |
| Revenue Next Year | $48.55 | $14.81 |
| P/E Ratio | ★ N/A | $49.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $393.61 | $11.55 |
| 52 Week High | $615.00 | $31.18 |
Technical Indicators
Market Signals| Indicator | MDGL | SRAD |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 43.69 |
| Support Level | $529.02 | $12.55 |
| Resistance Level | $545.13 | $13.90 |
| Average True Range (ATR) | 19.22 | 0.48 |
| MACD | 2.59 | 0.04 |
| Stochastic Oscillator | 77.29 | 23.13 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.